Skip to main content

Articles

Page 4 of 43

  1. Triglyceride glucose (TyG) index is considered a reliable alternative marker of insulin resistance and an independent predictor of cardiovascular (CV) outcomes. However, the prognostic value of TyG index in pa...

    Authors: Yue Zhang, Xiaosong Ding, Bing Hua, Qingbo Liu, Hui Gao, Hui Chen, Xue-Qiao Zhao, Weiping Li and Hongwei Li

    Citation: Cardiovascular Diabetology 2021 20:43

    Content type: Original investigation

    Published on:

  2. There are limited data on the association of diabetes mellitus (DM) and levels of glycated hemoglobin (HbA1c) with outcomes in patients with atrial fibrillation (AF).

    Authors: Andreas S. Papazoglou, Anastasios Kartas, Athanasios Samaras, Ioannis Vouloagkas, Eleni Vrana, Dimitrios V. Moysidis, Evangelos Akrivos, Georgios Kotzampasis, Amalia Baroutidou, Anastasios Papanastasiou, Evangelos Liampas, Michail Botis, Efstratios Karagiannidis, Nikolaos Stalikas, Haralambos Karvounis, Apostolos Tzikas…

    Citation: Cardiovascular Diabetology 2021 20:40

    Content type: Original investigation

    Published on:

  3. Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food an...

    Authors: Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2021 20:39

    Content type: Original investigation

    Published on:

  4. Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent dat...

    Authors: Giulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, Guy De Backer, Viveca Gyberg, Kornelia Kotseva, Linda Mellbin, Anna Norhammar, Jaakko Tuomilehto, David Wood and Lars Rydén

    Citation: Cardiovascular Diabetology 2021 20:38

    Content type: Original investigation

    Published on:

  5. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss

    Citation: Cardiovascular Diabetology 2021 20:37

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:208

  6. In this commentary, we introduce the concepts of removed and residual risks in conditioning thecardiorenal outlook of patients with type 2 diabetes (T2D). The removed cardiorenal risk represents the risk of pr...

    Authors: Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:36

    Content type: Commentary

    Published on:

  7. Epicardial adipose tissue (EAT) has anatomic and functional proximity to the heart and is considered a novel diagnostic marker and therapeutic target in cardiometabolic diseases. The aim of this study was to e...

    Authors: Emmanuel Cosson, Minh Tuan Nguyen, Imen Rezgani, Sopio Tatulashvili, Meriem Sal, Narimane Berkane, Lucie Allard, Pierre-Yves Brillet and Hélène Bihan

    Citation: Cardiovascular Diabetology 2021 20:35

    Content type: Original investigation

    Published on:

  8. Recently, the European Society of Cardiology (ESC) and European Association for the Society of Diabetes (EASD) introduced a new cardiovascular disease (CVD) risk stratification model to aid further treatment d...

    Authors: Suriya Prausmüller, Michael Resl, Henrike Arfsten, Georg Spinka, Raphael Wurm, Stephanie Neuhold, Philipp E. Bartko, Georg Goliasch, Guido Strunk, Noemi Pavo, Martin Clodi and Martin Hülsmann

    Citation: Cardiovascular Diabetology 2021 20:34

    Content type: Original investigation

    Published on:

  9. Hyperglycemia has been associated with increased inflammatory indexes and larger infarct sizes in patients with obstructive acute myocardial infarction (obs-AMI). In contrast, no studies have explored these co...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Donati, Michele Fabrizio, Chiara Chiti, Francesco Angeli, Sebastiano Toniolo, Andrea Stefanizzi, Matteo Armillotta, Paola Rucci, Gianmarco Iannopollo, Gianni Casella, Cinzia Marrozzini, Nazzareno Galiè and Carmine Pizzi

    Citation: Cardiovascular Diabetology 2021 20:33

    Content type: Original investigation

    Published on:

  10. While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at ...

    Authors: Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose and Naoki Kumashiro

    Citation: Cardiovascular Diabetology 2021 20:32

    Content type: Original investigation

    Published on:

  11. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Lei Guo, Junjie Wang, Huaiyu Ding, Shaoke Meng, Xiaoyan Zhang, Haichen Lv, Lei Zhong, Jian Wu, Jiaying Xu, Xuchen Zhou and Rongchong Huang

    Citation: Cardiovascular Diabetology 2021 20:31

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:100

  12. Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive.

    Authors: Tian Li, Rui Providencia, Nan Mu, Yue Yin, Mai Chen, Yishi Wang, Manling Liu, Lu Yu, Chunhu Gu and Heng Ma

    Citation: Cardiovascular Diabetology 2021 20:30

    Content type: Original investigation

    Published on:

  13. Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). Therefore, the purpose of our study was to investigate the clini...

    Authors: Yong Zhu, Shuai Meng, Maolin Chen, Kesen Liu, Ruofei Jia, Hong Li, Huagang Zhu and Zening Jin

    Citation: Cardiovascular Diabetology 2021 20:29

    Content type: Original investigation

    Published on:

  14. Atherogenic dyslipidaemia has been implicated in the residual risk for cardiovascular morbidity and mortality, which remains despite attainment of LDL cholesterol goals especially in individuals with type 2 di...

    Authors: Emanuela Orsi, Giuseppe Penno, Anna Solini, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Franco Cavalot, Susanna Morano, Marco G. Baroni, Antonio Nicolucci and Giuseppe Pugliese

    Citation: Cardiovascular Diabetology 2021 20:28

    Content type: Original investigation

    Published on:

  15. We sought to evaluate the association of metabolic syndrome (MetS) and computed tomography (CT)-derived cardiometabolic biomarkers (non-alcoholic fatty liver disease [NAFLD] and epicardial adipose tissue [EAT]...

    Authors: Andrew Lin, Nathan D. Wong, Aryabod Razipour, Priscilla A. McElhinney, Frederic Commandeur, Sebastien J. Cadet, Heidi Gransar, Xi Chen, Stephanie Cantu, Robert J. H. Miller, Nitesh Nerlekar, Dennis T. L. Wong, Piotr J. Slomka, Alan Rozanski, Balaji K. Tamarappoo, Daniel S. Berman…

    Citation: Cardiovascular Diabetology 2021 20:27

    Content type: Original investigation

    Published on:

  16. The independent role of pericardial adipose tissue (PAT) as an ectopic fat associated with cardiovascular disease (CVD) remains controversial. This study aimed to determine whether PAT is associated with left ...

    Authors: Jin-Seok Kim, Seon Won Kim, Jong Seok Lee, Seung Ku Lee, Robert Abbott, Ki Yeol Lee, Hong Euy Lim, Ki-Chul Sung, Goo-Yeong Cho, Kwang Kon Koh, Sun H. Kim, Chol Shin and Seong Hwan Kim

    Citation: Cardiovascular Diabetology 2021 20:26

    Content type: Original investigation

    Published on:

  17. Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) with or without heart failure (HF), the ...

    Authors: Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, Qiong Zhou, Yan Huang, Mei Zhai and Jian Zhang

    Citation: Cardiovascular Diabetology 2021 20:25

    Content type: Review

    Published on:

  18. There remain uncertainties regarding diabetes mellitus and the incidence of atrial fibrillation (AF), in relation to type of diabetes, and the interactions with sex and age. We investigated whether diabetes co...

    Authors: Arnaud Bisson, Alexandre Bodin, Grégoire Fauchier, Julien Herbert, Denis Angoulvant, Pierre Henri Ducluzeau, Gregory Y. H. Lip and Laurent Fauchier

    Citation: Cardiovascular Diabetology 2021 20:24

    Content type: Original investigation

    Published on:

  19. Diabetes patients without obstructive coronary artery disease as assessed by coronary angiography have a low risk of myocardial infarction, but their myocardial infarction risk may still be higher than the gen...

    Authors: Kevin Kris Warnakula Olesen, Morten Madsen, Christine Gyldenkerne, Pernille Gro Thrane, Troels Thim, Lisette Okkels Jensen, Hans Erik Bøtker, Henrik Toft Sørensen and Michael Maeng

    Citation: Cardiovascular Diabetology 2021 20:23

    Content type: Original investigation

    Published on:

  20. Insulin resistance carries increased risk of heart failure, although the pathophysiological mechanisms remain unclear. LV global longitudinal strain (LVGLS) assessed by speckle-tracking echocardiography has em...

    Authors: Kazutoshi Hirose, Koki Nakanishi, Masao Daimon, Naoko Sawada, Yuriko Yoshida, Kentaro Iwama, Yuko Yamamoto, Jumpei Ishiwata, Megumi Hirokawa, Katsuhiro Koyama, Tomoko Nakao, Hiroyuki Morita, Marco R. Di Tullio, Shunichi Homma and Issei Komuro

    Citation: Cardiovascular Diabetology 2021 20:22

    Content type: Original investigation

    Published on:

  21. To conduct a real-word-study-based cost-effectiveness analysis of a GLP-1 receptor agonist (GLP-1RA) versus insulin among type 2 diabetes patients requiring intensified injection therapy and a systematic revie...

    Authors: Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou and Shihchen Kuo

    Citation: Cardiovascular Diabetology 2021 20:21

    Content type: Original investigation

    Published on:

  22. The metabolic syndrome (MetS) and its components are associated with the development of atrial fibrillation (AF). However, the impact of time-burden of MetS on the risk of AF is unknown. We investigated the ef...

    Authors: Hyo-Jeong Ahn, Kyung-Do Han, Eue-Keun Choi, Jin-Hyung Jung, Soonil Kwon, So-Ryoung Lee, Seil Oh and Gregory Y. H. Lip

    Citation: Cardiovascular Diabetology 2021 20:20

    Content type: Original investigation

    Published on:

  23. The triglyceride–glucose (TyG) index, which is a simple surrogate marker of insulin resistance, has been suggested as a contributor of cardiovascular disease. However, evidence on the effect of long-term eleva...

    Authors: Xue Tian, Yingting Zuo, Shuohua Chen, Qian Liu, Boni Tao, Shouling Wu and Anxin Wang

    Citation: Cardiovascular Diabetology 2021 20:19

    Content type: Original investigation

    Published on:

  24. Mortality in individuals with diabetes with severe hypoglycemia requiring ambulance services intervention is high and it is unclear whether this is modifiable. Our aim was to characterise this high-risk group ...

    Authors: Sam M. Pearson, Beverley Whittam, Kavita Kulavarasalingam, Amelia Mitchell-Gears, Cathyrn James and Ramzi A. Ajjan

    Citation: Cardiovascular Diabetology 2021 20:18

    Content type: Original investigation

    Published on:

  25. Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for pati...

    Authors: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:17

    Content type: Review

    Published on:

  26. Patients with diabetes and triple-vessel disease (TVD) are associated with a high risk of events. The choice of treatment strategies remains a subject of discussion. In the real-world, we aim to compare the ou...

    Authors: Xueyan Zhao, Lianjun Xu, Lin Jiang, Jian Tian, Yin Zhang, Dong Wang, Kai Sun, Bo Xu, Wei Zhao, Rutai Hui, Runlin Gao, Lei Song and Jinqing Yuan

    Citation: Cardiovascular Diabetology 2021 20:16

    Content type: Original investigation

    Published on:

  27. Previous studies have suggested that high mean glucose levels and glycemic abnormalities such as glucose fluctuation and hypoglycemia accelerate the progression of atherosclerosis in patients with type 2 diabe...

    Authors: Satomi Wakasugi, Tomoya Mita, Naoto Katakami, Yosuke Okada, Hidenori Yoshii, Takeshi Osonoi, Nobuichi Kuribayashi, Yoshinobu Taneda, Yuichi Kojima, Masahiko Gosho, Iichiro Shimomura and Hirotaka Watada

    Citation: Cardiovascular Diabetology 2021 20:15

    Content type: Original investigation

    Published on:

  28. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with decreased risk of cardiovascular and renal event...

    Authors: Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji, Kengo Azushima, Shingo Urate, Toru Suzuki, Eriko Abe, Hiromichi Wakui and Kouichi Tamura

    Citation: Cardiovascular Diabetology 2021 20:14

    Content type: Original investigation

    Published on:

  29. Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulat...

    Authors: Stephen J. Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Michael Sweeney and Kausik K. Ray

    Citation: Cardiovascular Diabetology 2021 20:13

    Content type: Original investigation

    Published on:

  30. Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist...

    Authors: Preman Kumarathurai, Ahmad Sajadieh, Christian Anholm, Ole P. Kristiansen, Steen B. Haugaard and Olav W. Nielsen

    Citation: Cardiovascular Diabetology 2021 20:12

    Content type: Original investigation

    Published on:

  31. Patients with type 2 diabetes mellitus (T2DM) are susceptible to coexisted with chronic kidney disease (CKD), which may increase cardiovascular mortality in these patients. The present study aimed to verify wh...

    Authors: Yi Zhang, Jin Wang, Yan Ren, Wei-feng Yan, Li Jiang, Yuan Li and Zhi-gang Yang

    Citation: Cardiovascular Diabetology 2021 20:11

    Content type: Original investigation

    Published on:

  32. We investigated the association of insulin resistance (IR) with coronary plaque morphology and the risk of cardiovascular events in patients enrolled in the Providing Regional Observations to Study Predictors ...

    Authors: Serdar Farhan, Björn Redfors, Akiko Maehara, Thomas McAndrew, Ori Ben-Yehuda, Bernard De Bruyne, Roxana Mehran, Birgit Vogel, Gennaro Giustino, Patrick W. Serruys, Gary S. Mintz and Gregg W. Stone

    Citation: Cardiovascular Diabetology 2021 20:10

    Content type: Original investigation

    Published on:

  34. Risk stratification of cardiovascular events in patients with type 2 diabetes mellitus (T2DM) has not been established. Coronary artery calcium score (CACS) and non-alcoholic fatty liver disease (NAFLD) are in...

    Authors: Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita and Hiroshi Ito

    Citation: Cardiovascular Diabetology 2021 20:8

    Content type: Original investigation

    Published on:

  35. Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a...

    Authors: David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel and Felix Hohendanner

    Citation: Cardiovascular Diabetology 2021 20:7

    Content type: Original investigation

    Published on:

  36. In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitaliz...

    Authors: Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx and Michael Lehrke

    Citation: Cardiovascular Diabetology 2021 20:6

    Content type: Original investigation

    Published on:

  37. Evidence is limited about the joint health effects of the Mediterranean lifestyle on cardiometabolic health and mortality. The aim of this study was to evaluate the association of the Mediterranean lifestyle w...

    Authors: Mercedes Sotos-Prieto, Rosario Ortolá, Miguel Ruiz-Canela, Esther Garcia-Esquinas, David Martínez-Gómez, Esther Lopez-Garcia, Miguel Ángel Martínez-González and Fernando Rodriguez-Artalejo

    Citation: Cardiovascular Diabetology 2021 20:5

    Content type: Original investigation

    Published on:

  38. Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pres...

    Authors: Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi…

    Citation: Cardiovascular Diabetology 2021 20:4

    Content type: Original investigation

    Published on:

  39. Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated...

    Authors: Kamel Mohammedi, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, John Chalmers and Mark Woodward

    Citation: Cardiovascular Diabetology 2021 20:3

    Content type: Original investigation

    Published on:

  40. The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes. Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial structure and performance in...

    Authors: Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang and Zhengyuan Xia

    Citation: Cardiovascular Diabetology 2021 20:2

    Content type: Review

    Published on:

  41. Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiova...

    Authors: Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio, Alessandro Del Cuore, Mario Daidone, Tiziana Di Chiara, Domenico Di Raimondo, Vittoriano Della Corte, Carlo Maida, Irene Simonetta, Stefania Scaglione and Antonio Pinto

    Citation: Cardiovascular Diabetology 2021 20:1

    Content type: Original investigation

    Published on:

  42. It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been repor...

    Authors: Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Marija Vavlukis, Lucian Calmac, Tom Johnson, Gerard Roura i Ferrer, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Maurits Dirksen, Gianni Casella, Petr Kala…

    Citation: Cardiovascular Diabetology 2020 19:215

    Content type: Original investigation

    Published on:

  43. Type 2 diabetes (T2D) patients are at a greater risk of cardiovascular events due to aggravated atherosclerosis. Oxidized LDL (oxLDL) has been shown to be increased in T2D plaques and suggested to contribute t...

    Authors: Pratibha Singh, Isabel Goncalves, Christoffer Tengryd, Mihaela Nitulescu, Ana F. Persson, Fong To, Eva Bengtsson, Petr Volkov, Marju Orho-Melander, Jan Nilsson and Andreas Edsfeldt

    Citation: Cardiovascular Diabetology 2020 19:214

    Content type: Original investigation

    Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:61

  44. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Masatoki Yoshida, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Megumi Kondo, Kaoru Akazawa, Tomonari Kimura, Hiroaki Ohtsuka, Yuko Ohno, Daiji Miura and Hiroshi Ito

    Citation: Cardiovascular Diabetology 2020 19:213

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:149

  45. Heart failure is a common and devastating complication of type 2 diabetes (T2D). Prompt recognition of heart failure may avert hospitalization, facilitate use of guideline-directed therapies, and impact choice...

    Authors: Suzanne V. Arnold, Philip G. Jones, Michael Beasley, Jeanine Cordova, Abhinav Goyal, Gregg C. Fonarow and Leo Seman

    Citation: Cardiovascular Diabetology 2020 19:212

    Content type: Original investigation

    Published on:

  46. The aim of this study was to investigate the association of visit-to-visit variability of hemoglobin A1c (HbA1c) and glycated albumin (GA) with the risk of lower extremity atherosclerotic disease (LEAD).

    Authors: Yun Shen, Dongjun Dai, Jingyi Lu, Yufei Wang, Wei Zhu, Yuqian Bao, Gang Hu and Jian Zhou

    Citation: Cardiovascular Diabetology 2020 19:211

    Content type: Original investigation

    Published on:

  47. Ischemic heart disease (IHD) without diabetes is considered an important challenge to human health and is associated with a poor prognosis, as well as a lack of health awareness. We prospectively investigated ...

    Authors: Byoungjin Park, Yong-Jae Lee, Hye Sun Lee and Dong-Hyuk Jung

    Citation: Cardiovascular Diabetology 2020 19:210

    Content type: Original investigation

    Published on:

  48. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by targeting the low-density lipoprotein receptor. Recent studies have shown that circulating PCSK9 is associated with glu...

    Authors: Jie Shi, Weiwei Zhang, Yixin Niu, Ning Lin, Xiaoyong Li, Hongmei Zhang, Renming Hu, Guang Ning, Jiangao Fan, Li Qin, Qing Su and Zhen Yang

    Citation: Cardiovascular Diabetology 2020 19:209

    Content type: Original investigation

    Published on:

  49. We have previously reported that in patients with type 2 diabetes (T2D) consumption of a very low carbohydrate diet capable of inducing nutritional ketosis over 2 years (continuous care intervention, CCI) resu...

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss

    Citation: Cardiovascular Diabetology 2020 19:208

    Content type: Original investigation

    Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:37

journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

Cardiovascular Diabetology

ISSN: 1475-2840